ESMO 2022 | CompassHER2-pCR: de-escalation of neoadjuvant chemotherapy for breast cancer

Abirami Sivapiragasam, MD, Upstate Medical University, Syracuse, NY, provides an overview of the Phase II CompassHER2-pCR (NCT04266249) trial investigating de-escalation of neoadjuvant chemotherapy for patients who are HER2-positive stage II/III breast cancer stage. The standard of care for this patient population is docetaxel, carboplatin with trastuzumab and pertuzumab, and patients tend to have high rates of pathologic complete response (pCR). The COMPASSHER2-pCR trial is assessing whether carboplatin can be de-escalated after pre-surgery and targeted therapy whilst maintaining a good pCR. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.